AUTHOR INDEX Ailhaud,G. 145 Lontie, J.-F. 171 Alaupovic, P. 105, 151, 181, 275 Liikermann, R. 295 Attman, P. -O. 275 Ayrault-Jarrier, M. 151 Maeda, H. 281 Malmendier,C. L. 171 Bard, J. M. 267 Marcel, Y. L. 259 Bekaert,E.D. 151 Matsubara, T. 301 Bojanovski, D. 295 McConathy, W. J. 195, 237 Bojanovski, M. 295 Mercuri, O. 181 Borén, J. 205 Milne, R. W. 259 Brewer, H. B. Jr 139 Miyabo, S. 281 Brindley, D. N. 349 Burdelski, M. 295 Nakai, T. 281 Camato, R. N. 259 Oida, K. 281 Olofsson, S. -O. 205 Dahlén, G. H. 189 Dashti, N. 219 Deicroix, C. 171 Provost, P. 259 Delplanque, B. 159 Rader, D. J. 139 Fruchart, J.-C. 145 Rassart, E. 259 Fugate,R.D. 237 Richard, J. L. 159 Graham, L. 205 Salter, A.M. 349 Schinella, G. 181 ’ Schulz-Falten, J. 295 Hayashi, A. 301 Scott, J. 205 Sturm, E. 295 Innis, S. M. 39 Takahashi, S. 281 Jacotot, B. 159 Takau, H. 281 Tamai, T. 281 Tavella, M. 181 Kelley, J. L. 231 Tournier, H. 181 Knight-Gibson, C. 151, 181 Tremblay, N. M. 259 Kolesnick, R. N. 1 Trieu, V.N. 195 Koren, E. 237 Koscec, M. 237 Wang, C. -S. 253 Weech, P. K. 259 Lee, A. G. 323 Wettesten, M. 205 Lee, D. M. 245 White, A. 205 SUBJECT INDEX Acyl-CoA:sphingosine N-acyltransferase 14 fractionation of lipoprotein families 116, 119 Ca2+, Mg?*+-Adenosine triphosphatase, isolation and characterization 107 reconstituted with phosphatidylcholines 336, metabolic and functional properties of lipoprotein 340, 343 familes 122 Nat, K+-Adenosine triphosphatase, cholesterol production by HepG2 cells 222 effects 339 structure 205 Adipose tissue, n-6 and n-3 fatty acids during thiolester linkages in 245-252 development 58 Apolipoprotein B-containing lipoproteins 268 Adrenaline clinical interest 270 LDL receptor in liver 354 concanavalin A affinity chromatography 183 VLDL secretion 358 lipoprotein(a) interactions 196 Alagille syndrome 296-300 measurement 269 Alcohol, atherosclerosis and ApoA 149 pharmacological modulation 271 Aminoalkylphosphonic acids, FAB/MS_ 320 placenta 65 Anaesthetics, essential fatty acids and tolerance production by Caco-2 cells 227 to 79 production by HepG2 cells 224 Apolipoproteins renal insufficiency 277 chemical classification 112 Apolipoprotein B-48 283, 287 cholestasis 295-300 diabetes 288 diabetes 281-294 Apolipoprotein B-100 287 dyslipoproteinemias and atherosclerosis 125 biosynthesis 211 fractionation and characterization of lipoprotein intracellular transport 212 families 116 secretion 212 hormonal regulation 355 Apolipoprotein B-100 containing lipoproteins isolation and characterisation 107 assembly 211, 214 kinetics 142 fate of 207 markers of lipoprotein particles 112 secretion 212 metabolic and functional properties of lipoprotein secretory pathway 207, 210 families 122 Apolipoprotein C Apolipoprotein(a) isolation and characterization 107 atherosclerosis-thrombosis 192 in plasma 183 ligand binding 196 Apolipoprotein C-II structure 189, 195 functional domains 255 Apolipoprotein A gene mutation 257 cardiovascular disease 140 lipoprotein lipase interaction 256 cholestasis 299 structure 253 dietary fat 163 Apolipoprotein D 109, 259 dyslipoproteinemias 126 animal studies 262 fractionation of lipoprotein families 116, 118 clinical studies 265 HDL metabolism 141 immunochemistry 261 hereditary systemic amyloidosis 142 sites of gene expression 263 isolation and characterization 107 structure and properties 260 metabolic and functional properties of lipoprotein Apolipoprotein E 109 families 122 diabetes 285 Apolipoprotein A-containing lipoprotein macrophages 239 particles 268 plasma 183 clinical significance 147, 270 Apolipoprotein F 109 concanavalin A affinity chromatography 183 Apolipoprotein G 109 isolation and composition 146 Apolipoprotein H_ 110 measurement 269 Apolipoprotein J 110 pharmacological modulation 271 Atherosclerosis physiological role 146 alcohol and ApoA 149 production by Caco-2 cells 227 diabetes 282, 286, 353, 356 production by HepG2 cells 225 hormonal regulation 356, 358 quantitative determination 147 lipoprotein(a) 191 Apolipoprotein A-I deficiency, LP-A-Il in 154 lipoprotein A-I and B 270 Apolipoprotein A-I-lipoprotein particles, effect of lipoprotein families 128 diet 159 role of macrophages in regression 237-243 Apolipoprotein B sphingomyelin 7,8 atherosclerosis 129 dietary fat and secretion of 163, 221 Bacteriorhodopsin 331 dyslipoproteinemias 127 Biliary atresia 295-300 viii Subject Index Blood-brain barrier, n-6 and n-3 fatty acids 59 exogenous lipoproteins and atherogenesis 286 Breast gross cystic disease, ApoD 260, 265 lipoprotein abnormalities 283 Byler’s disease 295-300 Dietary fat effect on LP-A particles 148, 159 regulation of lipoprotein synthesis and Cardiovascular disease secretion 220 ApoA-containing lipoprotein particles 147 Dietary fatty acids 41, 74, 81, 160 diabetes 282, 286 N, N-Dimethylsphingosine 29 dietary fatty acids 159 Diphenylhexatriene 329 HDL 139 Dyslipoproteinemia lipoprotein(a) 189-194, 195-203 HDL metabolism 141 lipoprotein families 128, 270 lipoprotein families 125 Catecholamines renal insufficiency 276, 278 LDL receptor in liver 354 VLDL secretion 358 Ceramidases 15 ELISA, LP-A 269 Ceramide aminoethylphosphonate, FAB/MS 309 Endoplasmic reticulum, ApoB-100 207 Ceramide kinase 24 Endothelial cells, n-6 and n-3 fatty acids 60 Ceramide 1-phosphate 5, 24 Epidermal growth factor, effect of sphingoid Ceramides bases 27 degradation 15 Essential fatty acids 39-103 FAB/MS 316 clinical studies 81 measurement 5 CNS _ 50, 67 signal transduction 27 deficiency 41, 68 synthesis 14 desaturation in developing tissues 61 tissue distribution 7 development 50, 52, 56, 67, 90 Ceramidosis 15 diet 41, 74, 81 Cholestasis 295-300 growth 90 Cholesterol infant formulas 66 ApoA interaction 146 marine oils 75 degradation in macrophages 239 membranes 92 diabetes 287 metabolism 45, 58 dietary, regulation of lipoprotein synthesis and milk 65, 90 secretion 221 nomenclature 41 lipoproteins and metabolism 123 placental transfer 63 lipoprotein production by HepG2 cells 223 premature infants 81 low density lipoprotein receptor expression 359 recovery from deficiency 73 membrane protein interaction 339 uptake by brain 58 sphingomyelin interaction 7 Estrogens, LDL receptor expression 351, 355 Cholestyramine 271 Ethanol, essential fatty acids and tolerance to 79 Chylomicrons Ethanolamine phosphoglycerides apolipoproteins in 113 in blood, effect of dietary fat 82 diabetes 283, 286 in retina 51 VLDL secretion 357 CNS development, essential fatty acids 50, 52 Colestipol 272 Farber’s Lipogranulomatosis 15 Collisionary activated dissociation mass Fast atom bombardment mass spectrometry 302 spectrometry 303 aminoalkylphosphonic acids 320 Colonic carcinoma cells, lipoprotein ceramides 316 production 226 fatty acids 317 Concanavalin A affinity chromatography, gangliosides 315 lipoproteins 117, 181-187, 225 glycerophospholipids 305 Cyclohexanedione, modified LDL 174 glycoglycerolipids 312 glycosphingolipids 313 long chain bases 318 Desaturase phosphosphingolipids 309 in developing tissues 52, 61 sugars 318 essential fatty acid metabolism 45 sulfoglycolipids 315 Development Fatty acids adipose tissue, essential fatty acids 58 developing brain 52 CNS, essential fatty acids 50, 52, 67 dietary, effect on ApoA-lI particles in desaturation of n-6 and n-3 fatty acids 61 plasma 160 fatty acid uptake by brain 58 effect on lipoprotein production by HepG2 liver, essential fatty acids 56 cells 222 placental transfer of n-6 and n-3 fatty acids 63 essential, growth and development 39-103 Diacylglycerol kinase 24, 27 FAB/MS 317 1, 2-Diacylglycerols, sphingomyelin in LP-A and LP-B in plasma_ 185 degradation 20 thiolester-linked in ApoB 249 Diabetes Fenofibrate 271, 272 apolipoprotein abnormalities 285 a Fetoprotein 60 cardiovascular disease 282, 353, 356 Fish oil 48, 75, 89 Subject Index Gangliosides apolipoprotein composition and classification FAB/MS 315 105-138 in CNS, essential fatty acid deficiency 69 hepatic and intestinal secretion 220 GCDFP-24 260 hormonal regulation 355 Glomerulosclerosis 278 nutritional regulation of synthesis and Glucagon secretion 220 LDL receptor in liver 354 sphingomyelin in 7 VLDL secretion 358 Lipoprotein(a) Glucocorticoids atherosclerosis and thrombosis 189-194 LDL receptor in liver 353 interactions 195-203 VLDL secretion 356 Lipoprotein A containing particles 268 Glycerophospholipids clinical interest 270 blood, effect of dietary fat 81, 91 concanavalin A affinity chromatography developing brain 53 181-187 developing liver 56 measurement 269 essential fatty acids in 46, 47, 51 pharmacological modulation 271 FAB/MS 305 production by Caco-2 cells 227 milk 65 production by HepG2 cells 225 Glycolipids, FAB/MS 312 Lipoprotein A-I containing particles, effect of Glycosylated LDL 175 dietary fat 159 Growth, dietary essentiality of n-6 and n-3 fatty Lipoprotein A-II containing particles acids 41 characterization and isolation 152 putative role 155 Lipoprotein B containing particles Hemodialysis, lipoproteins 276, 277 Caco-2 cells 227 HepG2 cells, lipoprotein production by 125, clinical interest 270 222-226 concanavalin A affinity chromatography Hereditary systemic amyloidosis 142 181-187 High density lipoprotein HepG2 cells 224 apoprotein A 146 in vivo kinetics 177 apoprotein A-II 151 measurement 269 apoproteins in 113, 140 pharmacological modulation 271 cardiovascular disease 131, 139, 147, 155 renal insufficiency 277 diabetes 285 thiolester bonds 246 dietary fat 160 Lipoprotein lipase hepatic and intestinal secretion 220 ApoC-II interaction 256 metabolism 141 diabetes 283 renal insufficiency 275 renal insufficiency 277 Tangier disease 141 Lipoprotein receptors, diabetes 286 HMG CoA reductase inhibitors 272 Lipoprotein-X, cholestasis 296 Hypercholesterolemia, lipoproteins 128, 183, 271 Liver Hypertriglyceridemia, lipoproteins 128, 183 desaturases during development 61 LDL receptor, hormonal regulation 350 lipoprotein secretion 220 n-6 and n-3 fatty acids during development Infant formulas 56 fish oil 77 Long chain bases, FAB/MS_ 318 glycerophospholipids in blood 82 Long chain polyenoic fatty acids 39, 40 n-6 and n-3 fatty acids in 40, 66 clinical studies 81 Insulin CNS during development 50, 52 LDL receptor in liver 353 liver during development 56 lipoprotein production by HepG2 cells 223 metabolism 45 VLDL secretion 356 milk 65 Intermediate density lipoproteins 284, 349, 355 origin in developing tissues 58 Intestine, lipoprotein secretion 220 placental transfer 63 Longevity, ApoA particles 148 Low density lipoproteins KDEL type protein 213 apoproteins in 113 3-Ketosphinganine 17, 18 diabetes 284, 286 Kidney, lipoprotein abnormalities in renal hormones and catabolism 349-360 insufficiency 275-279 in vivo kinetics 172-180 lipoprotein(a) binding 196 macrophage scavenger receptors 231 Learning behaviour, essential fatty acids 79 plasminogen binding 198 Lecithin:cholesterol acyl transferase, ApoD receptor binding 174 association 261 Low density lipoprotein receptor 350 Lignoceryl-CoA:sphingosine N-acyltransferase 14, estrogens 351 15 glucagon and catecholamines 354 Lipid nutrition 41, 74, 81 insulin and glucocorticoids 353 Lipoproteins thyroid status 352 abnormalities in diabetic patients 283 VLDL secretion 355 Subject Index Lysosphingolipids, protein kinase C Protein kinase C, effect of sphingoid bases 20 inactivation 21 Protein motion 332 Psychosine 318 Macrophages degradation of cholesterol crystals 239 Renal insufficiency, lipoprotein abnormalities regression of atherosclerosis 237-243 275-279 Macrophage scavenger receptors 231 Retina, essential fatty acids 51, 79 purification and structure 232 Retinal rod outer segment disc membrane 343 regulation 233 Reverse cholesterol transport 155 Malondialdehyde, modified LDL 175, 232 Rhodopsin 343 Marine oils 75 Mass spectrometry/fast atom bombardment 301-322 Salvage compartment 213 Maternal diet Saponins, sphingomyelin degradation 13 n-6 and n-3 fatty acids in fetus 63 Scavenger receptor 231-235 n-6 and n-3 fatty acids in milk 66 diabetes 286 Membrane fluidity Secondary ion mass spectrometry 302, 303 essential fatty acids 79 Secretory proteins 206 phosphatidylcholine/sphingomyelin ratio 4 Serine palmitoyltransferase 17 phospholipid bilayers 328 Serine phosphoglycerides, in retina 51 proteins 335 Signal recognition particle 206 viscosity 323 Signal transduction, sphingomyelin and Membrane proteins, lipid effects 323-348 derivatives 20 Metarhodopsin 343 Simvastatin 271 Milk, n-6 and n-3 fatty acids in 40, 65, 90 Sphinganine 18 Monoclonal antibodies, ApoD 261 Sphinganine kinase 19 Monocyte-specific colony stimulating factor 233 Sphinganine 1-phosphate aldolase 19 Monounsaturated fatty acids, effect on Sphingenine, FAB/MS 318 apolipoproteins in plasma 163 Sphingoethanolamine, FAB/MS 308, 309 Motor skills, n-6 and n-3 fatty acids 78 Sphingoid bases Myelin degradation 19 essential fatty acid deficiency 69 measurement 5 essential fatty acids in 52, 55 protein kinase C inhibition 20 Myocardial infarction, lipoprotein(a) 191 synthesis 17 tissue distribution 7 Sphingomyelin 1-38 Niacin 272 cellular and tissue distribution 6 Niemann-Pick disease 8, 11 cholesterol metabolism 7 Noninsulin-dependent diabetes mellitus, ApoB-48 degradation 11, 20 metabolism 281-294 FAB/MS 309 measurement 5 physical properties 2 Oleate relationship with phosphatidylcholine 4 effect on lipoprotein production in Caco-2 signal transduction 20 cells 226 structure and composition 2 effect on lipoprotein production in HepG2 synthesis 9, 30 cells 222 Sphingomyelinase 22 Sphingosine effect on protein kinase C 20 Palmitoylated proteins 248 induced calcium release 31 Parenteral nutrition, essential fatty acids 43 measurement 6 Phorbol esters, protein kinase C activation 20 Stress, VLDL production 357 Phosphatidylcholine Sugars, FAB/MS_ 318 Ca2+, Mg2+-ATPase binding 336, 340, 343 Sulfoglycolipids, FAB/MS 315 FAB/MS 306 physical properties 3 Phosphatidylcholine:ceramide Tangier disease 120, 124 cholinephosphotransferase, sphingomyelin HDL metabolism 141 synthesis 10 Tetramethylammonium-diphenylhexatriene 331 Phospholipid bilayers, motion 328 Thiolester bonds, ApoB 245 Phospholipids, FAB/MS 305 Thrombosis, lipoprotein(a) 192 Phosphosphingolipids, FAB/MS 309 Thyroid status, LDL receptor in liver 352, 355 Phytosphingosine 19 Triglyceride-rich lipoproteins 124 Placenta, transfer of n-6 and n-3 fatty acids 63 coronary artery disease 129, 130 Plasminogen, binding to LDL, 198 diabetes 283, 288 Privastatin 271 renal insufficiency 275, 277 Premature infants, essential fatty acids 85 Triglycerides, lipoprotein(a) relationship 200 Proline, inhibition of LDL, binding to Apo(a) 198 Protein acylation 248 Protein disulfide isomerase 207, 213 Uremic dyslipoproteinemia 278 Subject Index Vegetarian nutrition, lipids in breast milk 82, 91 secretion and LDL catabolism 355 Very high density lipoprotein Tangier disease 124 apoproteins in 113 Viscosity, membrane fluidity 323 hepatic and intestinal secretion 220 Visual function, n-6 and n-3 fatty acids 78, 80, 92 Very low density lipoprotein Vitamin D3, induced phospholipid changes 25 apoproteins in 113 diabetes 283 renal insufficiency 276 Weaning foods, n-6 and n-3 fatty acids in 67